Mechanisms and Clinical Efficacy of Lixisenatide for the Management of Type 2 Diabetes

Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog

“…As suggested in humans (23,34), our data demonstrate a delay in gastric emptying following administration of lixisenatide that allows more efficient disposal of the carbohydrate in the meal. Data from mice and humans suggest that this may be accompanied by improved postprandial triglyceride and lipoprotein metabolism (29,37,38,65).…”

Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes

“…Intuitively, once-or twice-daily administration of 'short-acting' preparations of GLP-1 agonists, such as exenatide and lixisenatide, which predominantly diminish postprandial glucose by slowing GE [45,46], may have greater efficacy than once-weekly administration of longer-acting drugs, such as liraglutide and modified-release exenatide, where the slowing of GE appears to be modest with chronic use [45,46]. In summary, in healthy older individuals and patients with type 2 diabetes, acute i.v.…”

Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of Type 2 diabetes mellitus

“…Because of their effect on lowering body weight without increasing hypoglycemia, liraglutide and exenatide LAR are effective in combination with basal insulin [6]. Lixisenatide improves HbA 1c levels and enables a greater proportion of patients to achieve HbA 1c <7% [34]. In addition, lixisenatide has a beneficial effect on weight, with a limited risk of hypoglycemia and due to the slowing of gastric emptying, markedly reduces PPG levels.…”